Stay updated with breaking news from Optically Reversible. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- ILIAS Biologics Inc., a biotech company dedicated to developing a new treatment modality, engineered exosome therapeutics, announced today that...
Share this article Share this article DAEJEON, South Korea, Feb. 1, 2021 /PRNewswire/ -- ILIAS Biologics, Inc. announced that its latest research in collaboration with researchers at The University of Texas Medical Brand at Galveston (UTMB) is published in the journal Science Advances(Link: https://advances.sciencemag.org/content/7/4/eabd3865). The study showed successful results in preventing preterm birth and improving the fetus viability with ILB-202, ILIAS's anti-inflammatory exosomes developed through its EXPLOR® platform technology. This study result is the second proof of concept tha...
The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the 'fetus as the patient'.
E-Mail GALVESTON, Texas - The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the 'fetus as the patient'. The study has been published in Science Advances. It has long been suspected that pre-term labor is triggered by inflammation caused by a sick fetus. A new study by scientists at UTMB has proved the hypothesis by studying several important assumptions about the relationship between the health of a mother a...